Ledraxen (Enoxaparin Sodium)

Enoxaparin sodium enhances the activity of antithrombin III, leading to selective inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). This action reduces thrombin generation, limits fibrin clot formation, and provides anticoagulant protection in the venous system and extracorporeal circuits.

The dose of Ledraxen is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and risk factors. Healthcare professionals determine the appropriate amount and frequency according to current clinical guidelines and patient needs.

The pregnancy and lactation safety categories for Ledraxen are not definitively established. Use during pregnancy or while breastfeeding should only occur when the potential benefit justifies any potential risk to the fetus or infant, and after careful evaluation by a qualified healthcare provider.

To order Ledraxen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Compared with unfractionated heparin, enoxaparin (Ledraxen) has more predictable pharmacokinetics, a longer half‑life, and does not require routine laboratory monitoring in most patients. It offers a lower risk of heparin‑induced thrombocytopenia but still carries bleeding risk similar to other anticoagulants.

Ledraxen should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the solution, and keep it out of reach of children.

Ledraxen is supplied as a sterile injectable solution and can be given subcutaneously, intravenously, or incorporated into the haemodialysis circuit. Administration technique, injection site rotation, and aseptic handling are performed by trained healthcare professionals according to institutional protocols.

The most serious risks include major bleeding events such as intracranial or gastrointestinal hemorrhage, heparin‑induced thrombocytopenia (HIT), and spinal or epidural hematoma following neuraxial procedures. Prompt recognition of unusual bleeding or a rapid drop in platelet count is essential.

Ledraxen is contraindicated in patients with active major bleeding, known hypersensitivity to enoxaparin or other LMWHs, and those with severe uncontrolled hypertension. Caution is also advised for individuals with a history of HIT, recent spinal or epidural anesthesia, and severe renal impairment unless dose‑adjusted.